Welcome to our dedicated page for Restart Life news (Ticker: NMLSF), a resource for investors and traders seeking the latest updates and insights on Restart Life stock.
Restart Life Sciences Corp. (OTC Pink: NMLSF) is a Canadian-based life sciences company listed on the CSE under the symbol HEAL. This news page aggregates company announcements and developments related to its health and wellness product portfolio, financing activities, and strategic transactions.
Recent company news highlights the introduction and development of functional wellness brands such as BrainQ™ and BrainBalls™, which are described as supporting cognitive health, brain wellness, and overall well-being. Updates also cover the company’s food technology and research initiatives, which are intended to support ingredient assessment, formulation performance, and future product development across its brands.
Investors and observers can follow news about Restart Life Sciences’ capital-raising efforts, including non-brokered private placements, warrant exercises, and loan financings. The company reports that these financings are intended to fund health food trials, research initiatives, potential acquisitions, and general working capital.
A key topic in recent announcements is a binding letter of intent to acquire Holy Crap Foods Inc. from Happy Belly Food Group Inc., subject to customary conditions and regulatory approvals. News items describe how this proposed acquisition would add the Holy Crap brand portfolio and a co-packer production facility in British Columbia, supporting vertical integration and providing a platform for Restart Life Sciences’ own product lines.
By reviewing this news feed, readers can track how Restart Life Sciences communicates its progress on product launches, research programs, proposed acquisitions, and financing milestones within the health and wellness and functional food sectors.
Restart Life Sciences (OTC: NMLSF) closed an over-subscribed second tranche of a non-brokered private placement on December 18, 2025, raising gross proceeds of CDN$630,000 in the tranche and CDN$1,130,000 in total across two tranches.
The company issued 6,300,000 units at CDN$0.10 per unit; each unit includes one common share and one transferable warrant exercisable for one year at CDN$0.10. The company also issued 132,000 non-transferable finder warrants exercisable for one year at CDN$0.10. Proceeds are earmarked for health food trials, potential acquisitions, and general working capital. Securities are subject to a four-month-and-one-day hold expiring April 18, 2026.
Restart Life Sciences (OTC Pink: NMLSF) announced on December 17, 2025 that it will allocate capital to support newly planned food-related research initiatives aimed at its consumer health portfolio.
The company said it will narrow preferred research partners, pursue studies on ingredient quality, formulation performance, stability, sensory attributes and preliminary bioavailability, and expects findings to inform product refinement for brands such as BrainQ and BrainBalls. Additional updates will follow as research parameters and partnerships are defined.
Restart Life Sciences (OTC Pink: NMLSF) closed the first tranche of a non-brokered private placement on December 5, 2025, raising CDN$500,000 by issuing 5,000,000 units at CDN$0.10 per unit. Each unit includes one common share and one one-year warrant exercisable at CAD$0.10. The company paid CAD$16,800 in cash finder's fees and issued 60,000 non-transferable finder warrants exercisable at CAD$0.10 for one year. Proceeds are intended for health food trials, potential acquisitions, and general working capital. All securities are subject to a hold period ending April 6, 2026.
Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.
NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.
Summary not available.
Summary not available.
Summary not available.
Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the recruitment of participants for a pioneering clinical trial examining the effects of psilocybin on adults with fragile X syndrome (FXS). Conducted by its subsidiary KGK Sciences, the 28-day Phase IIA study is the first authorized by Health Canada allowing take-home psilocybin dosing. The study, set to treat its first participant in Q2 2023, aims to evaluate the safety and efficacy of Nova Mentis’ psilocybin drug (NM-1001) in a controlled environment, using advanced diagnostic technologies. Preliminary results are expected later this year, highlighting significant potential for psilocybin therapy in addressing unmet medical needs related to FXS.